drugset
drugset / Trial / NCT00222443

Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

NCT00222443 ↗

Phase 1 Completed 40 enrolled University of Oklahoma
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the response rate to this combination in children and adolescents with recurrent solid tumors and lymphomas.

Timeline

Start
2004-09
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 15 mg/m2 Intravenous

Indications

lymphoma